Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.

Finn R.S.Kudo, MasatoshiMasatoshiKudoMerle, PhilippePhilippeMerleMeyer, TimTimMeyerQin, ShukuiShukuiQinIkeda, MasafumiMasafumiIkedaXu, RuocaiRuocaiXuEdeline, JulienJulienEdelineRyoo, Baek-YeolBaek-YeolRyooRen, ZhenggangZhenggangRenANN-LII CHENGGalle, Peter R.Peter R.GalleKaneko, ShuichiShuichiKanekoKumada, HiromitsuHiromitsuKumadaWang, AnranAnranWangMody, KalgiKalgiModyDubrovsky, LeonidLeonidDubrovskySiegel, Abby B.Abby B.SiegelLlovet, Josep MJosep MLlovet2026-03-032026-03-032024-01-200732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/736062falseLenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.review article2-s2.0-105024659726